BACKGROUND: We assessed adherence to the European Society of Medical Oncology (ESMO)/Multinational Association of Supportive Care in Cancer recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (CINV) at our institution. PATIENTS AND METHODS: The charts of 299 patients starting a new chemotherapy between November 2008 and April 2009 were reviewed. Baseline characteristics and prophylaxis of CINV during the first cycle were recorded, and adherence to ESMO recommendations was determined. Chi-square tests and logistic regression were used to test for predictors of adherence. RESULTS: Prophylaxis of acute CINV was not adherent in 39% of the patients: 39 of 54 patients with low emetogenic chemotherapy had a serotonin antagonist, and 24 of 100 with moderately emetogenic therapy had a neurokinin antagonist. Nevertheless, 71% of the patients treated with highly emetogenic therapy received the guideline-specified prescription. Prophylaxis of delayed CINV was not adherent in 89% of the patients: 101 of 125 patients with highly or moderately emetogenic single-day chemotherapy received a serotonin antagonist. Male gender (odds ratio (OR) 0.484, 95% confidence interval (CI) 0.291-0.806; P = 0.005) and hematologic neoplasia (OR 2.151, 95% CI 1.19-3.887; P = 0.011) were independent predictors of non-adherence. Age (OR 0.981, 95% CI 0.964-0.998; P = 0.029) and inpatient treatment (OR 0.457, 95% CI 0.25-0.836; P = 0.011) indicated a lower risk of non-adherence. CONCLUSION: Contrary to older studies reporting frequent omissions of corticosteroids, the current study demonstrated significant overuse of serotonin antagonists for prophylaxis of delayed CINV.
BACKGROUND: We assessed adherence to the European Society of Medical Oncology (ESMO)/Multinational Association of Supportive Care in Cancer recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (CINV) at our institution. PATIENTS AND METHODS: The charts of 299 patients starting a new chemotherapy between November 2008 and April 2009 were reviewed. Baseline characteristics and prophylaxis of CINV during the first cycle were recorded, and adherence to ESMO recommendations was determined. Chi-square tests and logistic regression were used to test for predictors of adherence. RESULTS: Prophylaxis of acute CINV was not adherent in 39% of the patients: 39 of 54 patients with low emetogenic chemotherapy had a serotonin antagonist, and 24 of 100 with moderately emetogenic therapy had a neurokinin antagonist. Nevertheless, 71% of the patients treated with highly emetogenic therapy received the guideline-specified prescription. Prophylaxis of delayed CINV was not adherent in 89% of the patients: 101 of 125 patients with highly or moderately emetogenic single-day chemotherapy received a serotonin antagonist. Male gender (odds ratio (OR) 0.484, 95% confidence interval (CI) 0.291-0.806; P = 0.005) and hematologic neoplasia (OR 2.151, 95% CI 1.19-3.887; P = 0.011) were independent predictors of non-adherence. Age (OR 0.981, 95% CI 0.964-0.998; P = 0.029) and inpatient treatment (OR 0.457, 95% CI 0.25-0.836; P = 0.011) indicated a lower risk of non-adherence. CONCLUSION: Contrary to older studies reporting frequent omissions of corticosteroids, the current study demonstrated significant overuse of serotonin antagonists for prophylaxis of delayed CINV.
Authors: R J Gralla; D Osoba; M G Kris; P Kirkbride; P J Hesketh; L W Chinnery; R Clark-Snow; D P Gill; S Groshen; S Grunberg; J M Koeller; G R Morrow; E A Perez; J H Silber; D G Pfister Journal: J Clin Oncol Date: 1999-09 Impact factor: 44.544
Authors: Paul J Hesketh; Steven M Grunberg; Richard J Gralla; David G Warr; Fausto Roila; Ronald de Wit; Sant P Chawla; Alexandra D Carides; Juliana Ianus; Mary E Elmer; Judith K Evans; Klaus Beck; Scott Reines; Kevin J Horgan Journal: J Clin Oncol Date: 2003-10-14 Impact factor: 44.544
Authors: Martee L Hensley; Karen L Hagerty; Tarun Kewalramani; Daniel M Green; Neal J Meropol; Todd H Wasserman; Gary I Cohen; Bahman Emami; William J Gradishar; R Brian Mitchell; J Tate Thigpen; Andy Trotti; Daniel von Hoff; Lynn M Schuchter Journal: J Clin Oncol Date: 2008-11-17 Impact factor: 44.544
Authors: F Roila; M Tonato; F Cognetti; E Cortesi; G Favalli; M Marangolo; D Amadori; M A Bella; V Gramazio; D Donati Journal: J Clin Oncol Date: 1991-04 Impact factor: 44.544
Authors: Kunal C Kadakia; Alexis D Leal; Drew K Seisler; Rui Qin; Kelliann C Fee-Schroeder; Darryl C Grendahl; Kristine M Sorgatz; Charles L Loprinzi Journal: Support Care Cancer Date: 2013-09-13 Impact factor: 3.603
Authors: Yasmeen Razvi; Stephanie Chan; Thomas McFarlane; Erin McKenzie; Pearl Zaki; Carlo DeAngelis; William Pidduck; Ahmad Bushehri; Edward Chow; Katarzyna Joanna Jerzak Journal: Support Care Cancer Date: 2018-10-03 Impact factor: 3.603
Authors: Andrea Tendas; Fabio Sollazzo; Pasquale Niscola; Luca Cupelli; Maria Rita Mauroni; Antonella D'Apolito; Vittoria Pilozzi; Stella Cacciaraichi; Caterina Viggiani; Adriana Concetta Pignatelli; Ombretta Annibali; Andrea Mengarelli; Teresa Dentamaro; Paolo de Fabritiis; William Arcese Journal: Support Care Cancer Date: 2012-08-01 Impact factor: 3.603
Authors: David Church; Rachel Kerr; Enric Domingo; Dan Rosmarin; Claire Palles; Kevin Maskell; Ian Tomlinson; David Kerr Journal: Nat Rev Cancer Date: 2014-05-15 Impact factor: 60.716
Authors: Michelino De Laurentiis; Chiara Bonfadini; Vito Lorusso; Giuseppina Cilenti; Francesca Di Rella; Giuseppe Altavilla; Manuela Otero; Antonio Ardizzoia; Paolo Marchetti; Giorgia Peverelli; Domenico Amoroso; Stefania Vecchio; Elena Fiorio; Simona Orecchia Journal: Support Care Cancer Date: 2018-06-25 Impact factor: 3.603
Authors: Matti Aapro; Florian Scotté; Yolanda Escobar; Luigi Celio; Richard Berman; Alessandra Franceschetti; Danielle Bell; Karin Jordan Journal: Oncologist Date: 2021-03-17
Authors: Mary Lou Affronti; Susan M Schneider; James E Herndon; Susan Schlundt; Henry S Friedman Journal: Support Care Cancer Date: 2014-02-26 Impact factor: 3.603